EUROPEAN CURRICULUM VITAE FORMAT

PERSONAL INFORMATION

Name	**CONTE PIERFRANCO**
Address	San Camillo Hospital, IRCCS Via Alberoni 70,30126 Venezia Lido000
Telephone	+39 041 2207629
E-mail	pierfranco.conte@unipd.it pierfranco.conte@hsancamillo.it
Nationality	Italian
Date of birth	October 5, 1950

WORK EXPERIENCE

• Dates (from -to)	04/2022 – present
Name and address of the employer	SCIENTIFIC DIRECTORATE and RESEARCH SERVICES S Camillo Hospital, IRCCS, Venezia
• Position held	Scientific Director
Dates (from-to)	05/2021 - present
Name and address of the employer	Periplo Foundation, Genova
Position held	Chairman
• Dates (from – to)	04/2021 – 03/2022
• Name and address of the employer	SCIENTIFIC DIRECTORATE and RESEARCH SERVICES Istituto Oncologico Veneto, IRCCS, Padova
• Position held	Scientific Director
Dates (from – to)	09/2021 – 12/2023
Name and address of the employes	Molecular Tumor Board of Veneto Region, Padova
Position held	Chairman
• Dates (from – to)	06/2014 – 09/2021
• Name and address of the employer	Breast Unit (HUB Center), Istituto Oncologico Veneto, IRCCS, Padova
• Occupation or position held	Chairman
• Dates (from – to)	02/2014 – 09/2024
• Name and address of the employer	Rete Oncologica Veneta Istituto Oncologico Veneto, IRCCS, Padova
• Occupation or position held	Chairman

• Dates (from – to)	02/2013 – 09/2021
• Name and address of the employer	Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova
• Occupation or position held	Chief
• Dates (from – to)	11/2002 – 01/2013
• Name and address of the employer	Division of Medical Oncology, University Hospital, Modena
• Occupation or position held	Chief
• Dates (from – to)	12/2002-8/2008
• Name and address of the employer	Department of Oncology & Hematology, University Hospital, Modena
• Occupation or position held	Director
• Dates (from – to)	1990-2002
• Name and address of the employer	Division of Medical Oncology, Saint Chiara Hospital Pisa
• Occupation or position held	Director
• Dates (from – to)	1985-90
• Name and address of the employer	Division of Medical Oncology, National Institute for Cancer Research, Genova
• Occupation or position held	Deputy Head,
• Dates (from – to)	1980-85
• Name and address of the employer	Division of Medical Oncology, National Institute for Cancer Research, Genova
• Occupation or position held	Assistant Professor
• Dates (from – to)	1978-80
• Name and address of the employer	Institute of Oncology, S. Giovanni Hospital, Torino
• Occupation or position held	Assistant Professor Division of Medical Oncology
• Dates (from – to)	1976-78
• Name and address of the employer	University of Torino School of Medicine
• Occupation or position held	Postdoctoral fellowship in Hematology
• Dates (from – to)	1975-76
• Name and address of the employer	Universite' Libre de Bruxelles Dept. of Molecular biology, Bruxelles
• Occupation or position held	Postdoctoral fellowship

RESEARCH EXPERIENCE

• Dates (from-to)	2016-Present
• Name and type of organisation	University of Padua
• Main Activities	A-BRAVE Trial phase III randomized trial of an anti-pd-l1 antibody as adjuvant or post-neoadjuvant treatment for high-risk triple negative breast cancer patients

• Dates (from-to)	2013-Present
• Name and type of organisation	University of Padua
• Main Activities	MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance Aromatase

	Inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients with HR + metastatic breast cancer with disease control after first line chemotherapy
• Dates (from-to)	2013-Present
• Name and type of organisation	Veneto Government
• Main Activities	Impact of the Oncotype DX® Breast Cancer Assay on Resources Optimization and Treatment Decisions for Women with Estrogen Receptor- Positive, Node-Negative and Node-Positive Breast Carcinoma: a prospective Italian multicenter study
• Dates (from-to)	2013-Present
• Name and type of organisation	University of Padua
• Main Activities	PIK3CA pathway activation and tumor infiltrating lymphocytes (TIL) to predict outcome of HER+ early breast cancer (EBC) patienys treated with trastuzumab based therapy in the prospective randomized phase III Short-Her trial.
• Dates (from-to)	2009-2012
• Name and type of organisation	Ministry of Health
• Main Activities	Treatment optimization of HER2 positive breast cancer (PI)
• Dates (from-to)	2002-2011
• Name and type of organisation	Industry sponsored trials
• Main Activities	PI of 129 trials in solid tumours (56 breast, 11 gastro-enteric, 31 genitourinary, 24 lung, 5 melanoma, 2 CNS)
• Dates (from-to)	2008-2011
• Name and type of organisation	AIFA
• Main Activities	PI of the ShortHer Trial: national trial sponsored by the Italian Drug Agency (AIFA) to compare 9 weeks vs 1 year of adjuvant trastuzumab in HER2+ early breast cancer
• Dates (from-to)	2007-2009
• Name and type of organisation	Emilia Romagna Regional Government
• Main Activities	Identification and clinical validation of predictive and prognostic factors with special focus on molecularly targeted agents (PI)
• Dates (from-to)	2006-2008
• Name and type of organisation	Ministry of Health
• Main Activities	Validation of new biomarkers: role in prognosis and therapy guidance (PI)
• Dates (from-to)	2003-2007
• Name and type of organisation	• AIRC • Ministry of Research and Education
• Main Activities	Tumour molecular subtypes and Primary Systemic Treatment with targeted agents in Operable Breast Cancer (PI)
• Dates (from-to)	2001-2003
• Name and type of organisation	CNR
• Main Activities	Development of Chemotherapy regimens based on the tumor molecular profile (PI)
• Dates (from - to)	1998-2000
• Name and type of organisation	AIRC
• Main Activities	Clinical studies to improve treatment outcomes in metastatic breast cancer patients (PI)
• Dates (from-to)	1998
• Name and type of organisation	CNR
• Main Activities	Evaluation of Positron Emission Tomography in breast cancer (PI)
• Dates (from-to)	1991-96
• Name and type of organisation	Special project Clinical application of oncologic research, ACRO, CNR
• Main Activities	Accelerated vs conventional chemotherapy in locally advanced breast cancer (PI)

• Dates (from-to)	1989-92
• Name and type of organisation	AIRC
• Main Activities	Biologic modifiers: in vitro and in vivo effects on cancer cells (PI)
• Dates (from-to)	1987-89
• Name and type of organisation	AIRC
• Main Activities	Cytokinetic chemotherapy in breast cancer (PI)
• Dates (from - to)	1984-89
• Name and type of organisation	Special Project Oncology, PFO, CNR
• Main Activities	Determination of growth fraction as a prognostic indicator and to design clinical trials in ovarian and breast cancer (PI)
• Dates (from - to)	1982-83
• Name and type of organisation	Special Project Oncology, PFO, CNR
• Main Activities	Determination of growth fraction as a prognostic indicator and to design clinical trials in ovarian and breast cancer (PI)
• Dates (from-to)	1982-83
• Name and type of organisation	Committee for technological research, CNR
• Main Activities	Development of autoradiographic technique to study the growth fraction of human tumors in vitro (PI)

ACCADEMIC POSITION

• Dates (from - to)	02/2013- 09/2021
• Name and type of organisation	University of Padova
• Principal subjects covered	Clinical Oncology
• Title of qualification awarded	Full Professor
• Dates (from - to)	11/2002-02/2013
• Name and type of organisation	Modena School of Medicine
• Principal subjects covered	Clinical Oncology
• Title of qualification awarded	Full Professor
• Dates (from-to)	1993 – 2002
• Name and type of organisation	Pisa School of Medicine
• Principal subjects covered	Clinical Oncology
• Title of qualification awarded	Professor

EDUCATION AND TRAINING

• Date	1984
• Name and type of organisation providing education and training	Genova University
• Principal subjects/occupational skills covered	Hematology
• Title of qualification awarded	Specialty
• Date	1980
• Name and type of organisation providing education and training	Milano University
• Principal subjects/occupational skills covered	Clinical Immunology
• Title of qualification awarded	Specialty

• Dates	1977
• Name and type of organisation providing education and training	Torino University
• Principal subjects/occupational skills covered	Clinical Oncology
• Title of qualification awarded	Specialty
• Date	1974
• Name and type of organisation providing education and training	Torino University
• Title of qualification awarded	M.D.
MOTHER TONGUE	**Italian**
OTHER LANGUAGES	
	English
• Reading skills	EXCELLENT
• Writing skills	EXCELLENT
• Verbal skills	EXCELLENT

ANNEXES

Research Grants
Committee and Chairmanship
Awards
Scientific Publications
Scientific Affiliations
Editorial Board
Editorial Reviewer Board

I conducted clinical research according to GCP.

Research Grants

Grants with the National Research Council (CNR)

- 1982-83 "Development of autoradiographyc (PDP test) and cytofluorimetric techniques to study in vitro the growth fraction of human tumors"
- 1984-89 "Measurement of the growth fraction as a prognostic parameter and to design clinical protocols in breast and ovarian carcinoma"
- 1991-96 "Accelerated versus conventional chemotherapy in locally advanced breast cancer"
- 1998-99 "Evaluation of PET in breast carcinoma"
- 1999-2001 "Preoperative chemotherapy with the GET regimen in operable breast carcinoma"
- 2001-2003 "Design of anthracycline/taxane regimens according to the tumoral biological profile"

Grants with the Italian Association for Cancer Research (AIRC)

- 1987-89 "Cytokinetic chemotherapy of breast cancer"
- 1989-92 "Biological modifiers: in vitro and in vivo effects on neoplastic cells"
- 1996-97 "Special Project Stem Cell in Oncology: selection and in vitro expansion of CD 34+ HSC derived from bone marrow and peripheral blood to support single or multiple cycles of high dose chemotherapy"
- 1998-2000 "Clinical studies to improve treatment outcomes in metastatic breast cancer patients",
- 2003-2004 "Operable Breast Cancer : an in vivo model to integrate target directed therapies in the management of operable breast cancer"

Grants with the Ministry of Research and Education

- 2005-2007 “Primary systemic therapy for early breast cancer: clinical, biological and molecular outputs”

Grants with the Ministry of Health

- 2006-2008 “Validation of new biomarkers: role in prognosis and therapy guidance”
- 2009-2012 “Treatment optimization of HER2 positive breast cancer”
- 2017- ongoing “Monitoring recommendations on innovative oncology drugs: development, adherence, clinical outcomes and pharmacoeconomical impact”

Grants with other State Agencies

- 2004-2007 “Gene therapy of solid tumors”- Interchange Program Italy-Hungaria- Italian Ministry for Foreign Affairs
- 2007-2009 “Short-HER: multicentric randomised phase III trial of adjuvant chemotherapy plus 3 vs 12 months of trastuzumab in breast cancer patients with HER2 positive disease”-AIFA-Italian Drug Agency

Grants with Regional Agencies

- 1995-1996 “Pharmacokinetic evaluation of paclitaxel“ – Research Program of the Tuscany Government
- 2007-2009 “Identification and clinical validation of predictive and prognostic factors with special focus on molecularly targeted agents” – Research Program of Emilia Romagna Government – University
- 2013 “Impact of the Oncotype DX® Breast Cancer Assay on Resources Optimization and Treatment Decisions for Women with Estrogen Receptor- Positive, Node-Negative and Node-Positive Breast Carcinoma: a prospective Italian multicenter study” - Veneto Government
- 2014 PRITHA project: “Organizational systems for patients with bone metastases in the Venetian Oncology Network”
- 2017 – ongoing “Adherence to PDTA as evaluation of appropriateness, sustainability and quality in the treatment of breast and lung cancers:measuring, reproducing and determining efficiency of indicators”.

Grants with University of Padua

- 2013 present – MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance Aromatase Inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients with HR + metastatic breast cancer with disease control after first line chemotherapy
- 2013 present - PIK3CA pathway activation and tumor infiltrating lymphocytes (TIL) to predict outcome of HER+ early breast cancer (EBC) patienys treated with trastuzumab based therapy in the prospective randomized phase III Short-Her trial.
- 2016 present – A-BRAVE Trial PHASE III RANDOMIZED TRIAL OF AN ANTI-PD-L1 ANTIBODY AS ADJUVANT OR POST-NEOADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS

Commitee and Chairmanship

- Founder and Chairman, Gruppo Oncologico Nord-Ovest 1983-1998
- Secretary, Italian Association of Medical Oncology (Liguria Section) 1984-1989
- Chairman, Italian Association of Medical Oncology (Liguria Section) 1989-1990
- Member, Executive Committee of the Italian Society of Cell Kinetics 1989-1992
- Member, Steering Committee International Cancer Cooperative Group (ICCG) 1992-2010
- Member, National Executive Committee, Italian Association of Medical Oncology 1992-1993
- Chairman, Italian Association of Medical Oncology (Toscana Section) 1997-1999
- Member, National Executive Committee of the Italian Cancer Society 1997-1999
- Member, Board of Directors Bioethical Committee, Tuscany Regional Government 1993-1999
- Member, Meta-Analysis Group in Cancer 1994-2010
- Member, National Cancer Committee of the Ministry of Health1997-1999
- Faculty Member, European Society of Medical Oncology (ESMO) 1998-present
- Member, Clinical Discussion Forum European Society for Medical Oncology (Expert on Breast Cancer and Ovarian Cancer) 2002-present
- Founder and Chairman, Association Translation Research Oncology (ASTRO) 2002-2022
- Referee, Italian Ministry of Health for the Continuous Medical Education (ECM) program 2002-present
- Vice Chairman, Cancer Committee, Emilia Romagna Regional Government 2006- 2012
- Member of the Anti Cancer Drug Committee of the Italian Drug Agency (AIFA) 2008- 2010
- Founder and Chairman, Association Research Education Oncology (AREO) 2009-2010
- Chairman, Veneto Oncology Network, 2004-2014

- Founder , Association Onlus PERIPLO 2017
- Founder nd Chairman, PERIPLO Foundation 2022-present
- Scientific Advisor; Oncology Committee, AIFA 2023-present

Awards

- 2007 Recipient of the Claude Jacquillat Award for Achievement in Clinical Oncology
- 2015 Stelle della Fenice in the world Award
- 2018 Promotion of Clinical Research Award from AIOM (Italian Association Medical Oncology)

Scientific Affiliations

- Italian Association Medical Oncology (AIOM)
- Italian Cancer Society (SIC)
- European Society Medical Oncology (ESMO)
- American Society Clinical Oncology (ASCO)
- The Cell Kinetics Society
- International Gynecologic Cancer Society
- The New York Academy of Sciences
- Italian Society Basic & Applied Cell Kinetics (SICCAB)
- New England Cancer Society (Honorary Member)

Editorial Board (past and ongoing)

- Clinical Breast Cancer
- Journal of Clinical Oncology
- Oncologie
- The Breast Journal
- Trends in Medicine
- The Oncologist
- Cancers

Editorial Reviewer Board

- Acta Hematologica
- Annals of Oncology
- British Journal of Cancer
- Cancer
- Clinical Drug Investigation
- Critical Review Oncology&Hematology
- Drugs
- European Journal of Cancer
- Expert Opinion in Pharmacotherapy
- Future Medicine
- Gynecologic Oncology
- Journal of Clinical Oncology
- Lancet
- Oncology
- Seminars in Oncology
- Tumori

Scientific Publications

- Prof. Conte has published about 600 papers in Peer Reviewed Journals. The majority of papers regard the biological characterization and clinical trials in ovarian and breast cancer
- as of september 2024 **Total H Index = 83 (SCOPUS)**
- Total citations: n. **33857**

I authorize the processing of personal data contained in my curriculum vitae according to art. 13 of Legislative Decree 196/2003 and art. 13 of EU Regualation 2016/679 on the protection of individuals with regard to the processing of personal data.

Padua September 11, 2024

Si autorizza il trattamento dei dati contenuti in questo document

Pierfranco Conte